Can a Pre-Surgery drug tame metastatic kidney cancer?
NCT ID NCT00715442
First seen Jan 11, 2026 · Last updated Jun 21, 2026 · Updated 24 times
Summary
This phase 2 trial is studying whether giving the drug sunitinib before surgery to remove a kidney can help control metastatic renal cell carcinoma. About 50 patients with kidney cancer that has spread will take sunitinib for 28 days, then have the affected kidney removed. Researchers are tracking how long it takes for the cancer to progress and any side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sunitinib (Sutent), a cancer drug taken by mouth
What this could lead to
If successful, this approach could help control metastatic kidney cancer before surgery, potentially improving outcomes.
What could go wrong
This is a small, early-phase trial with only 50 participants. The drug may cause serious side effects, and it is not yet known if it truly improves survival or disease control.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.